News, Short Squeeze, Breakout and More Instantly...
Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition. In fact, it's fair to say that a lot of biotech comp...
Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel PR Newswire - New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SA...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Invitae (NYSE: NVTA ) have had a disastrous 2022 so far. Today, the genetic information company is down more than 10%, bringing its year-to-date decline to more than 60%. Source: Connect world / Shutterst...